"The
Report Global PARP Inhibitor Market: Size, Trends and Forecasts
(2016-2020) provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
The
report titled Global PARP Inhibitor Market: Size, Trends and
Forecasts (2016-2020) provides an in-depth analysis of the global
PARP inhibitor market with detailed analysis of market size on the
basis of value along with the comprehensive examination of each of
the segments of the market, namely, Lynparza, Niraparib, Rucaparib,
Talazoparib and Veliparib.
The
report analyses the global Lynparza market in detail along with the
regional analysis as it is the only commercialized product in the
market. The clinical trials of Niraparib, Rucaparib, Talazoparib and
Veliparib are also summarized along with the anticipated market
commencement for each of the products.
The
report provides detailed market potential of PARP inhibitor in
Ovarian cancer, Breast cancer, Prostate cancer and Pancreatic cancer.
This section provides the detailed analysis of the clinical trials of
various PARP inhibitors for the concerned cancer treatment.
The
report also assesses the key opportunities in the market and outlines
the factors that are and will be driving the growth of the industry.
Growth of the overall global PARP inhibitor market has also been
forecasted for the period 2016-2020, taking into consideration the
research & development, the growth drivers and the current and
future trends. The competition in the global PARP inhibitor market is
stiff and dominated by the big players like AstraZeneca. Further, key
players in the market, AbbVie, Clovis Oncology, Medivation and Tesaro
are also profiled with their financial information and respective
business strategies.
View Report At :
http://www.marketresearchreports.biz/analysis/866444
Regional Coverage
- Global
Company Coverage
- AstraZeneca PLC
- AbbVie Inc.
- Clovis Oncology, Inc.
- Medivation, Inc.
- Tesaro, Inc.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/866444
Executive Summary
The global PARP inhibitor
market has flourished since 2015 as in late 2014, the first PARP
inhibitor product was launched and projections are made that the
market would rise in the next five years i.e. 2016-2020 tremendously.
The market is spread across the globe with the United States and
Europe dominating the market.
The PARP inhibitor market can
be segmented on the basis of the products into Lynparza, Niraparib,
Rucaparib, Talazoparib and Veliparib. Currently, Lynparza is the only
commercialized product in the market while other four products are in
the development/trial stage. The market for Veliparib is expected to
flourish since 2017 while the markets for Niraparib, Rucaparib and
Talazoparib is expected to commence from 2018.
The
major growth drivers for the global PARP inhibitor market are: rise
in cancer incidences and PARP inhibitors in clinical routine. Despite
the market is governed by growth drivers, there are certain
challenges faced by the market such as: side-effects of PARP
inhibitors and resistance to PARP inhibition. Some of the recent and
major trends in the market include, various PARP inhibitors in the
pipeline, inhibiting enzyme versus PARP trapping, the combination of
PARP inhibitor & c-MET and pill burden likely to decline in the
near future.
Read
our latest Press Release at
http://www.marketresearchreports.biz/pressreleases
Table
of Contents
1. Executive Summary
2. Introduction
2.1 DNA Damage Response (DDR)
2.2 DNA Damage Response (DDR)
Drug Portfolio
2.3 PARP Inhibitor
2.3.1 Introduction to PARP
Inhibitor
2.3.2 Inhibiting PARP Mechanism
2.3.3 PARP Inhibitor as a
Cancer Treatment
2.3.4 PARP Inhibitor
Development
3. Global Market Analysis
3.1 Global PARP Inhibitor
Market by Value
3.2 Global PARP Inhibitor
Market by Segments
3.2.1 Global Lynparza Market
Analysis
Ongoing Lynparza Trials
Global Lynparza Market by Value
Global Lynparza Market by
Region
3.2.2 Global Niraparib Market
Analysis
Ongoing Niraparib Trials
Global Niraparib Market by
Value
3.2.3 Global Rucaparib Market
Analysis
Ongoing Rucaparib Trials
Global Rucaparib Market by
Value
3.2.4 Global Talazoparib Market
Analysis
Ongoing Talazoparib Trials
Global Talazoparib Market by
Value
3.2.5 Global Veliparib Market
Analysis
Ongoing Veliparib Trials
Global Veliparib Market by
Value
4. Global PARP Inhibitor Market
Potential Analysis
4.1 Global PARP Inhibitor
Market Potential
4.2 Global Ovarian Cancer
Market Opportunity
4.3 Global Breast Cancer Market
Opportunity
4.4 Global Prostate Cancer
Market Opportunity
4.5 Global Pancreatic Market
Opportunity
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Rise in Cancer Incidences
5.1.2 PARP Inhibitors in
Clinical Routine
5.2 Challenges
5.2.1 PARP Inhibitors
Side-Effects
5.2.2 Resistance to PARP
Inhibition
5.3 Market Trends
5.3.1 PARP Inhibitors in
Pipeline
5.3.2 Inhibiting Enzyme and
PARP Trapping
5.3.3 Combination of PARP
Inhibitors and c-MET
5.3.4 PARP Inhibitor Pill
Burden
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment